Key result
Resveratrol in combination with doxorubicin has been reported to prevent cardiac toxicity and exert a synergistic effect against tumor cells both in vivo and in vitro.
Why the study?
Does resveratrol prevent doxorubicin-induced cardiotoxicity?
Does resveratrol prevent doxorubicin-induced cardiotoxicity?
Resveratrol shows potential as a protective agent against doxorubicin-induced cardiotoxicity based on preclinical in vivo and in vitro studies.
Hypothesis-generating for resveratrol with doxorubicin; leaves open confirmation in clinical trials.
Doxorubicin is the mainstay of treatment for various haematological malignancies and solid tumours. However, its clinical application may be hampered by dose-dependent cardiotoxicity. The mechanism of doxorubicin-induced cardiotoxicity may involve various signalling pathways including free radical generation, peroxynitrite formation, calcium overloading, mitochondrial dysfunction and alteration in apoptosis and autophagy. Interestingly, the use of resveratrol in combination with doxorubicin has been reported to prevent cardiac toxicity as well as to exert a synergistic effect against tumour cells both in vivo and in vitro. Thus, the aim of this review is to summarize current knowledge and to elucidate the protective effect of resveratrol in doxorubicin-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2015) conducted a review in Doxorubicin-induced cardiotoxicity. Resveratrol was evaluated. Resveratrol in combination with doxorubicin has been reported to prevent cardiac toxicity and exert a synergistic effect against tumor cells both in vivo and in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: